AI MARKET SCANNING

AIM ImmunoTech Inc.

📅 Next Catalyst: Nov 16, 2026 (🌙 Close) 🏛️ NYSE American 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +1.47%
MAX GAP RECORD +12.00%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $AIM
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 16, 2026 Earnings Release 2026-11-16 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 07, 2026 Earnings Release 2026-08-07 (AFTER CLOSE)
-10.34%
May 15, 2026 Earnings Release 2026-05-15 (AFTER CLOSE)
+12.00%
Mar 27, 2026 Earnings Release 2026-03-27 (AFTER CLOSE)
+1.43%
Nov 17, 2025 Earnings Release 2025-11-17 (AFTER CLOSE)
+0.69%
Aug 14, 2025 Earnings Release 2025-08-14 (AFTER CLOSE)
+0.39%
May 15, 2025 Earnings Release 2025-05-15 (AFTER CLOSE)
+0.00%
Mar 27, 2025 Earnings Release 2025-03-27 (BEFORE OPEN)
+0.00%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.7%
Bullish Gaps (5)
Bearish Gaps (2)
Neutral / Flat (2)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $AIM

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome;…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗